Altered trafficking of mutated growth factor receptors and their associated molecules: Implication for human cancers

Shunsuke Kon1, Nobuhide Kobayashi1 and Masanobu Satake1,*

1Institute of Development, Aging and Cancer, Tohoku University; Sendai, Japan

Keywords: endocytosis, endosomes, lysosomes, membrane vesicles, oncogenesis, receptor tyrosine kinase, signal transduction, ubiquitination

Abbreviations: AML, acute myeloid leukemia; CMML, chronic myelomonocytic leukemia; EE, early endosomes; EGFR, epidermal growth factor receptor; ER, endoplasmic reticulum; FLT3, fms-like tyrosine kinase 3; HGF, hepatocyte growth factor; ITD, internal tandem duplication; KIT, tyrosine-protein kinase; LE, late endosomes; MDS, myelodysplastic syndrome; MET, mesenchymal epithelial transition factor; MVB, multivesicular bodies; RE, recycling endosomes; RTK, receptor tyrosine kinase; T-ALL, T cell acute lymphoblastic lymphoma

Ligand-stimulated receptor tyrosine kinases (RTKs) are phosphorylated/ubiquitinated, endocytosed and transported to the lysosomes via endosomes/multivesicular bodies, resulting in the attenuation of signal transmission. If this physiological mechanism of RTK signal downregulation is perturbed, signal transmission persists and may contribute to cellular transformation. This article presents several such examples. In some cases, endocytosis is impaired, and the activated RTK remains on the plasma membrane. In other cases, the activated RTK is endocytosed into endosomes/multivesicular bodies, but not subsequently sorted to the lysosomes for degradation. The latter cases indicate that even endocytosed RTKs can transmit signals. Transport of RTKs is accomplished via the formation and movement of membrane vesicles. Blockage or delay of endocytosis/trafficking can be caused by genetic alterations in the RTK itself or by mutations in CBL, Arf GAPs, or other components involved in internalization and vesicle transport. A survey of the literature indicates that, in some cases, even RTKs synthesized de novo can initiate signaling at the endoplasmic reticulum/Golgi before reaching the plasma membrane. The spectrum of molecules targeted by the signal is likely to be different between cell surface- and endoplasmic reticulum/Golgi-localized RTKs.

Introduction

Growth factor receptors on the cell surface comprise three parts: an extracellular domain for ligand binding, a transmembrane domain, and an intracellular domain harboring a tyrosine kinase domain. Binding of an extracellular ligand triggers intracellular autophosphorylation of the receptor tyrosine kinase (RTK) followed by adaptor association, recruitment and phosphorylation of associated kinases, and the activation of downstream signaling molecules. The eventual outcome of this signal transmission is either a positive or a negative effect on the growth of the cell. It must be noted that ligand-induced activation of RTKs occurs only transiently. Phosphorylated RTKs are then ubiquitinated, triggering internalization into endocytic endosomes via clathrin-dependent or -independent pathways. The early endosomes (EE) are the site of cargo sorting, at which point it is determined whether RTKs will be recycled back to the plasma membrane via recycling endosomes (RE), or transported to the lysosomes via late endosomes (LE)/multivesicular bodies (MVB). In lysosomes, RTKs are enzymatically degraded, which downregulates the signal. Under physiological conditions, growth-stimulating signals are transient due to the above-mentioned mechanisms of signal downregulation, which are necessary to prevent unlimited cell growth. By contrast, if cells should acquire the capacity to escape these downregulating mechanisms, persistent transmission of growth-promoting signals could become a causative mechanism of oncogenesis.

Growth-promoting signals are believed to be elicited mainly from activated RTKs located on the cell surface; however, when RTKs are endocytosed into the cytoplasm, they may not be automatically downregulated. Thus, the first question to be addressed is whether endocytosed activated RTKs continue to participate in signal transduction. Similarly, new RTK polypeptides are synthesized at the endoplasmic reticulum (ER) and then transported to and glycosylated in the Golgi apparatus. Newly synthesized RTK molecules on their way to the plasma membrane have been believed to be inactive because of the unavailability of ligand in the cytoplasmic membrane-bound organelles. A second question is whether RTKs synthesized de novo are capable of initiating signaling, particularly when the RTK is activated by mutation.
Accumulated evidence indicates that the answers to these two questions are indeed yes. In this mini-review, we describe several examples of these phenomena and discuss the significance of altered trafficking of mutated RTKs in human oncology.

**Implication of altered trafficking of mutated RTKs on cancer**

**Epidermal growth factor receptor (EGFR)**

The L858R point mutation resides in the tyrosine kinase domain of EGFR and is frequently associated with non-small cell lung cancer (Fig. 1).\(^5\)\(^-\)\(^7\) This mutation results in impaired endocytosis of EGFR.\(^8\) Although L858R-EGFR is internalized after EGF stimulation, its internalization occurs more slowly than that of wild-type EGFR, so it remains intact on the cell surface for a longer time. Since the tyrosine phosphorylation of mutant EGFR is increased and prolonged, downstream signal transduction is also more strongly activated, as reflected by the increased phosphorylation of ERK, AKT and STAT3. The L858R mutation causes defective coupling to CBL, an E3 ubiquitin-conjugating enzyme. The poorly ubiquitinated mutant EGFR is therefore endocytosed less efficiently. Note that Y1045 of mutant EGFR, the CBL-docking site, is well phosphorylated, but that phosphorylation of CBL is poor. The authors suggest that the weak association between L858R-EGFR and CBL is probably related to the formation of a heterodimer between L858R-EGFR and HER2, another member of the EGFR family.\(^8\) This heterodimerization appears to occur even in the absence of ligand stimulation.

The type III variant of EGFR, EGFRvIII, is a mutant (deletion of amino acid residues 6–273) found in various types of cancers, including those of the brain, lung, prostate and ovary (Fig. 1).\(^9\)\(^-\)\(^12\) This deletion in the extracellular domain renders the receptor incapable of binding EGF. Instead, the tyrosine residues in EGFRvIII are phosphorylated independently of ligand engagement, but

\[\text{Figure 1. Cancer/leukemia-associated mutations found in RTKs. The numbers in the figure correspond to those of the amino acid sequences registered in the NCBI Reference Sequence. The loci IDs of human EGFR, MET, KIT and FLT3 polypeptides are NP_005219.2, NP_000236, NP_000213 and NP_004110, respectively. Note that Y1045 of EGFR described in the text corresponds to Y1069 in the figure, and that D1246 and M1268 of MET described in the text are numbered in NP_001120972 and correspond to D1228 and M1250 in the figure, respectively. Black boxes represent transmembrane domains, whereas slashed boxes represent tyrosine kinase domains. PM, plasma membrane; v III, variant type 3; del, deletion; ITD, internal tandem duplication.}\]
Interestingly, roughly half of the mutated MET molecules are constitutively phosphorylated, even in the absence of transforming cells in vitro and in vivo (MET, an experimentally introduced mutation, is capable of in the juxta-transmembrane domain of MET, and the Y1003F is expressed in various types of epithelial cells. Y1003 is located at a much lower level compared with EGF-stimulated wild-type EGFR. Y1045, whose phosphorylation is necessary for EGFR to recruit CBL, is also barely phosphorylated in EGFRvIII. Y1003 serves as a CBL-docking site. Therefore, Y1003F-MET is only poorly ubiquitinated, even after HGF stimulation, although tyrosine phosphorylation in the cytoplasmic tail is unaffected by the mutation. Thus, phosphorylated but not ubiquitinated Y1003F-MET is endocytosed from the cell surface, transported to the EE/RE and sorted to LE/MVB as efficiently as wild-type MET. This means that ubiquitination of MET is dispensable for its endocytosis and transport to MVB. However, tyrosine phosphorylation of Hrs, an essential component of MVB, does not occur in cells with Y1003F-MET, thus preventing the mutated MET from being transported to the lysosomes. This results in a substantial delay in the degradation of Y1003F-MET, which remains intact in its phosphorylated form. This causes persistent activation of downstream signaling molecules, including H-RAS, MEK and ERK. An important implication of the above findings is that both cell surface-activated MET and endocytosed cytoplasmic MET are capable of transducing signals to the downstream molecules.

The two mutations in MET D1246N and M1268T were originally identified in papillary renal carcinomas and are located in the kinase domain (Fig. 1). The tyrosine residues of mutated MET are constitutively phosphorylated, even in the absence of HGF. Interestingly, roughly half of the mutated MET molecules are located on the cell surface, while the remaining molecules are detected in the cytoplasm. This cytoplasmic, mutated MET resides in the EE and RE, as indicated by its colocalization with EEA1 and Rab11, respectively. When internalization and recycling are assessed individually, both are substantially increased in cells with mutated MET, indicating that active shuttling occurs between the plasma membrane and the EE/RE.

Mutated MET is constitutively active and can elicit signals to downstream molecules. RAC1 is activated, inducing remodeling of the actin cytoskeleton (namely, disappearance of stress fibers), and cell migration is stimulated. All of these events appear to confer a transformed phenotype to cells expressing mutated MET. Importantly, blocking the endocytosis of mutated MET abolishes RAC1 activation, reducing cell migration and cell transformation. Thus, in the case of constitutively active MET in the absence of HGF ligation, it is likely that cytoplasmic MET localized to endosomes is responsible for the induction of cellular transformation.

Tyrosine-protein kinase (KIT)
D816V is a mutation in KIT found in certain subtypes of human acute myeloid leukemia (AML). As shown in Figure 1, D816 is located in the kinase domain of KIT, and D816V-KIT represents a ligand-independent, constitutively active form of the protein. When overexpressed in human cells, human D816V-KIT is mainly distributed on the Golgi apparatus and, to a lesser extent, the plasma membrane, and is capable of transforming cells. Strangely, when expressed in murine cells, the same protein is synthesized de novo and retained on the ER, but fails to reach either the Golgi apparatus or the plasma membrane, and is not able to transform cells. However, the expression of a truncated form of human D816V-KIT, which is comprised primarily of the intracytoplasmic domain (but not the extracellular domain or transmembrane domain), is still capable of transforming murine cells. This truncated protein appears to be distributed throughout the cytoplasmic membrane-bound organelles, including the Golgi apparatus, but is not present on the cell surface. Thus, for D816V-KIT to transform cells, ER retention is not sufficient, Golgi localization is sufficient, and plasma membrane localization is dispensable.

In murine cells, the intracytoplasmic domain of D816V-KIT can transduce signals to downstream molecules, including ERK, AKT and STAT3, whereas the ER-retained intact form of D816V-KIT can activate ERK, but not AKT or STAT3.

Fms-like tyrosine kinase 3 (FLT3)
An internal tandem duplication (ITD) mutation in FLT3 occurs in the juxta-transmembrane domain of the protein. This mutation is also associated with AML (Fig. 1). FLT3-ITD is a constitutively active form and is therefore autophosphorylated at Y591 (and Y842) independently of ligand binding. With regard to its subcellular localization, FLT3-ITD is detected not only on the cell surface but also on the ER. To examine the different signaling activities elicited by cell surface FLT3-ITD and ER-located FLT3-ITD, various techniques have been employed. These strategies include the use of chemical compounds, such as tunicamycin and brefeldin A, as well as the introduction of FLT3-ITD molecules that contain modifications, such as the deletion of an extracellular domain or tagging of the myristoylation motif. FLT3-ITD located on the cell surface activates the RAS-MAPK (phosphorylation of ERK) and PI3K (phosphorylation of AKT) pathways, whereas FLT3-ITD located in the ER activates STAT5. This differential signaling elicited by differentially localized FLT3-ITD molecules appears to be applicable to both overexpressed and endogenous proteins. Furthermore, it is similar to the signaling activity observed for KIT-ITD, another mutation associated with AML.

Implication of CBL mutations on RTK signaling and cancer
CBL encodes an E3 ubiquitin ligase and contains a phosphotyrosine-binding domain and a Ring finger domain. Interaction...
with activated RTKs is mediated by the phosphotyrosine-binding domain, whereas ubiquitination of RTKs occurs via the Ring finger domain. Ubiquitination of RTKs is generally believed to trigger endocytosis and subsequent degradation, the main mechanism of downregulation of RTK signaling.

R420Q is a mutation of CBL found in an AML patient. R420 lies in a site of contact between CBL and the E2 ubiquitin-conjugation enzyme UbcH7. Although R420Q-CBL can associate with FLT3, the mutated CBL only weakly ubiquitinates FLT3. Thus, the ligand-induced internalization of RTKs, including FLT3 and EGFR, is substantially delayed in R420Q-CBL-expressing cells, resulting in increased RTK signaling as evidenced by sustained phosphorylation of ERK. Eventually, the R420Q mutation of CBL induces cellular transformation.

Chronic myelomonocytic leukemia (CMML) presents a unique pattern of gene alteration involving CBL. In this condition, an allele from one parent is lost, whereas another allele from the other parent is duplicated, thus giving rise to an apparently normal diploidy (called acquired uniparental disomy).

Loss of one allele is in accordance with the concept of CBL as a tumor suppressor, since CBL is involved in downregulating ligand-induced RTK signaling. By contrast, the duplicated allele is found to harbor various missense mutations in the Ring finger domain that are positioned at the E2-binding interface. Note that these mutations are often duplicated due to uniparental disomy. This results in some apparently paradoxical observations. On one hand, bone marrow cells from CBL(−/−) mice exhibit increased colony-forming activity, indicating that CBL functions as a tumor suppressor gene. On the other hand, cells transduced by missense-mutated CBL also exhibit a transformed phenotype, indicating that CBL acts as a proto-oncogene. Because of the locations of the mutations in CBL, its enzymatic activity as an E3 ubiquitin ligase is reduced. In addition, and more importantly, CBL molecules containing mutations such as Q367P and Y371S tend to attenuate the activity of wild-type CBL when both are coexpressed. As a result, ubiquitination of RTKs, including KIT, FLT3, JAK2 and EGFR, is inhibited, allowing prolongation of RTK signaling. In this sense, the mutated CBL appears to exert a...
gain-of-function effect on wild-type CBL. It must be noted here that, in the CMMIL samples, one allele of CBL is lost, whereas the other allele is duplicated. Therefore, it is possible that mutated CBL negatively regulates other members of the CBL family, such as CBL-B.25

**Involvement of the Arf GAPs AGFG1 and SMAP1 in transferrin receptor/RTK trafficking and cancer**

Arf genes form a family that encodes small GTPases belonging to the RAS superfamily. GTPase-activating proteins (GAPs) mediate the conversion of the GTP-bound, active form of a GTPase to the GDP-bound, inactive form. There are 31 human genes that encode Arf GAPs, most of which are implicated in the process of vesicle formation from membranes.26 Arf GAPs exert negative regulation of Arf GTPase to the GDP-bound, inactive form. There are even cases in which mutated RTKs synthesized as CBL-B.25 CBL negatively regulates other members of the CBL family, such as CBL-B.25

**HIP1 and CTTN in RTK trafficking and cancer**

The Huntingtin interacting protein 1 (HIP1) is involved in clathrin-mediated endocytosis.35-39 HIP1 associates and colocalizes with clathrin and the adaptor protein AP-2. In human prostate and breast cancers, HIP1 is overexpressed.40 The effects of HIP1 overexpression have been investigated in multiple cell lines.41 In these cells, expression of EGF (and transferrin receptor) is substantially upregulated, and its auto- and ligand-induced phosphorylation is increased. Accordingly, intracellular uptake and accumulation of EGF (and transferrin) is increased, resulting in the activation of a downstream signaling cascade, including RAS/MEK/ERK and PI3K signaling. This increased signaling activity likely serves as the basis for cellular transformation.

Cortactin (CTTN) is a multidomain protein that connects membrane endocytosis and the actin cytoskeleton.42 CTTN binds both filamentous actin and dynamin2, and regulates the fission of budding vesicles. In human tumors of the breast, and head and neck regions, CTTN is amplified and overexpressed,43,44 and the effects of CTTN overexpression have been investigated in multiple cell lines.45 In these cells, EGF-induced phosphorylation and internalization of EGFR is not altered. However, phosphorylation of CBL and its association with EGFR is impaired, resulting in poor ubiquitination of EGFR. Thus, upon EGF stimulation in CTTN-overexpressing cells, downregulation of EGFR is delayed and impaired. Persistent activation of downstream signals, such as ERK, appears to be responsible for the increased growth of CTTN-overexpressing cells.

**Caveats and perspectives**

*Figure 2* summarizes a view on altered trafficking of RTK and cancer. The view is deduced from the literature survey mentioned above, and is also supported by previous reviews.46-49 In some cases, endocytosis is impaired, and the activated RTK remains on the plasma membrane. In other cases, the activated RTK is incorporated and passed to EE/MVB, but not subsequently sorted to the lysosomes for degradation. Thus, perturbation of downregulating mechanisms of activated RTK can cause persistent signal transduction and contribute to cellular transformation. There are even cases in which mutated RTKs synthesized
de novo can initiate signaling at the ER/Golgi before reaching the plasma membrane.

It must be noted that the literature cited above mainly focuses on RTK signaling but not on the trafficking machinery. For example, multiple endocytic pathways exist, including clathrin-dependent, caveolin-dependent and clathrin- and caveolin-independent pathways. The case of deregulation of RTK endocytosis, it is not immediately clear which of the above three pathways is involved, and whether or not the choice of pathway affects the nature of the deregulation. For example, we described that EGF-bound EGFR is ubiquitinated by CBL and then endocytosed. However, according to Sigismund et al., this ubiquitination occurs only at high concentrations of EGF (20 ng/ml in cell culture). At low concentrations of EGF (1.5 ng/ml), almost all (~100%) cell surface EGFR is endocytosed via clathrin-coated vesicles. Ubiquitination of EGFR is dispensable for this type of endocytosis, and the incorporated EGFR is efficiently transported to the EE. Most of the EGFR molecules (~70%) are then recycled back to the plasma membrane via RE, leaving only a minor fraction (~30%) destined for degradation. Since knock-down of clathrin accelerates the decay of phosphorylated AKT, recycling of EGFR via clathrin-coated vesicles is thought to contribute to the sustainability of EGFR signaling. Y1045F (see Fig. 1) is an experimentally introduced mutation, and Y1045F-EGFR provides a model for the study of RTKs endocytosed via clathrin-coated vesicles, since this molecule escapes ubiquitination.

By contrast, again according to Sigismund et al., when high concentrations of EGF are used, 60% of the cell surface EGFR molecules undergo endocytosis via clathrin-coated vesicles, as described above, whereas the remaining 40% are endocytosed independently of clathrin, perhaps via a caveolar pathway. Filipin is an experimental reagent used to test the significance of clathrin-independent endocytosis. The reagent interferes with cholesterol, which is enriched in membrane rafts/caveolae. For this type of endocytosis, modification of cargo via mechanisms such as ubiquitination is indispensable, and most ubiquitinated EGFRs are sorted from the EE to the LE/lysosomes for degradation. Therefore, this clathrin-independent endocytosis is involved in downregulating EGFR signaling and is mobilized in response to high levels of ligand stimulation. The differential usage of endocytic pathways should be taken into consideration when analyzing the fate of mutated and oncogenic RTKs.

In addition, although only endocytosis-lysosomal degradation has been reviewed here, autophagy-lysosomal degradation might also be used. In fact, a few cases were reported in which a component of this pathway is involved in human cancers. TSG101, a component of ESCRT-I, is one example. Paradoxically, overexpression of TSG101 is reported in thyroid cancer, suggesting a role as an oncogene, whereas deletion of the same gene is found in breast cancer, suggesting a role as a tumor suppressor. Thus, the significance of RTK degradation via the autophagy-lysosomal pathway in oncogenesis awaits further analysis.

We have been impressed, in the literature survey described above, by the existence of only a few reports, at the most, in which mutations of RTKs or their associated molecules are oncogenic due to altered trafficking. Thus, we wonder whether the mechanisms by which RTKs escape downregulation might be only weakly oncogenic, compared with RTK overexpression through gene amplification and/or promoter modification, and so less frequently encountered in cancer samples. Alternatively, little attention might have been paid to date to altered trafficking in oncology.

In this review article, altered membrane trafficking was re-visited only from the point of view of RTKs and their associated molecules. We took this approach because RTKs promote cell growth and because we observed aberrant trafficking of KIT in SMAP1-deficient and MDS-bearing mice. However, cancer development involves not only tumor initiation but also progression to a malignant invasive/metastatic phenotype. In addition to cell growth, cell motility, cell-cell adhesion, cell de-differentiation, epithelial-mesenchymal transition and mesenchymal-epithelial transition contribute to cancer progression. Thus, analysis of endocytosis, recycling and degradation of molecules involved in these steps, for example E-cadherin and integrin, constitutes a significant field in oncology research that needs to be reviewed separately.

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

References
1. Blume-Jensen P, Hunter T. Oncogenic kinase signal-ling. Nature 2001; 411:355-65; PMID:11357143; http://dx.doi.org/10.1038/sjłó77225
2. Dikic I, Giordano S. Negative receptor signal-ling. Curr Opin Cell Biol 2003; 15:128-35; PMID:12648667; http://dx.doi.org/10.1016/S0955-0674(03)00004-8
3. Peschard P, Paik M. Escape from Chl-mediated downregulation: a recurrent theme for oncogenic deregulation of receptor tyrosine kinases. Cancer Cell 2003; 3:519-23; PMID:12842080; http://dx.doi.org/10.1016/S1535-6108(03)00136-3
4. Waterman H, Yarden Y. Molecular mechanisms underlying endocytosis and sorting of ErbB recep-tor tyrosine kinases. FEBS lett 2001; 490:142-52; PMID:11223029; http://dx.doi.org/10.1016/S0014-5793(01)02172-7
5. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haselrat SM, Sukpo JG, Haluska FG, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350:2129-39; PMID:1518073; http://dx.doi.org/10.1056/NEJMoaa049938
6. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304:1497-500; PMID:1518125; http://dx.doi.org/10.1126/science.1099314
7. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, Singh B, Heelan R, Rausch V, Fulton L, et al. EGFR receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004; 101:13006-11; PMID:15529413; http://dx.doi.org/10.1073/pnas.040520101
8. Shigemign K, Kochupuzakal BS, Zang Y, Pines G, Starr A, Vexler A, Citri A, Katz M, Lavi S, Ben-Basat Y, et al. Defective ubiquitylation of EGFR mutants of lung cancer confers prolonged signaling. Oncogene 2007; 26:6968-78; PMID:17486068; http://dx.doi.org/10.1038/sj.onc.1215013
9. Moscatello DK, Holgado-Madruga M, Godwin AK, Ramirez G, Gunn G, Zollick PW, Biegel JA, Hayes RL, Wong AJ. Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res 1995; 55:5536-9; PMID:7585629
10. Okamoto I, Kenyon LC, Emlet DR, Mori T, Sasaki J, Hirokuno S, Ichikawa Y, Kishi H, Godwin AK, Yoshida M, et al. Expression of constitutively ac-tivated EGFFrIII in non-small cell lung cancer. Cancer Sci 2003; 94:50-6; PMID:12708474; http://dx.doi.org/10.1111/j.1349-7006.2003.tb01351.x
11. Olapade-Olopa EO, Moscetto DL, MacKay EH, Horvath B, Sandha DP, Terry TR, Wong AJ, Habib FK. Evidence for the differential expression of a variant EGF receptor protein in human prostate cancer. Br J Cancer 2000; 82:186-94; PMID:10638888.

12. Grandal MV, Zandi R, Pedersen MW, Willumsen B, Andersen JS, Nielsen LB, Hørning EK. Expression of the Akt family of serine/threonine kinases in adenocarcinoma of the breast. J Pathol 2002; 197:51-7; PMID:12025664; http://dx.doi.org/10.1002/path.825.

13. Grossman D, Hantman D, Price MJ, Yee J, Fowlkes JL, Di Martino A, Wang Y, Steitz JA, Krust A, Lai ZW, et al. The 3'-untranslated region of the mouse TTS1 gene is required for normal tissue-specific expression and plays a role in the development of the immune system. Cell 2004; 117:691-703; PMID:15187356; http://dx.doi.org/10.1016/j.cell.2004.05.034.

14. Aguilera V, Espevik T, Rustgi AK, Langenbach R, Batycky RJ, et al. c-Cbl and the clathrin coat: partners in physiologic endocytosis. Mol Biol Cell 2000; 11:1841-51; PMID:10815570; http://dx.doi.org/10.1091/mbc.11.7.1841.

15. Thoene C, Langenbach R. Role of c-Cbl in clathrin-dependent endocytosis. Biochim Biophys Acta 2002; 1560:1-13; PMID:12042034; http://dx.doi.org/10.1016/S0304-4165(02)00209-2.

16. Segura-Carretero S, De La Torre J. Clathrins and their coat proteins. Nat Rev Mol Cell Biol 2007; 8:624-35; PMID:17804540; http://dx.doi.org/10.1038/nrm2152.

17. Costa-Cabral P, Zhang L, Langenbach R. Interactions of the clathrin coat protein clathrin-associated protein 1 with the adaptor protein epsin. Mol Biol Cell 2003; 14:3443-56; PMID:12898414; http://dx.doi.org/10.1091/mbc.E03-02-0116.

18. Hætten K, Langenbach R. Membrane traffic and cancer. Nat Rev Cancer 2009; 9:549-59; PMID:19643316; http://dx.doi.org/10.1038/nrc2657.

19. Høiby E, Pless E, Talavera C, Madsen E, Skovsted H, et al. Proteomic analysis of the clathrin coat and identification of novel clathrin-binding proteins. Mol Cell Proteomics 2011; 10:1518-31; PMID:21533457; http://dx.doi.org/10.1074/mcp.M110.008870.

20. Gilliland DG, Griffin JD. The roles of FLT3 in human hematopoiesis and leukemia. Blood 2002; 99:2021-8; PMID:11844380; http://dx.doi.org/10.1182/blood-2001-08-1585.

21. Hoebe K, Tolhuis J, van der Voort T. Clathrin-based endocytosis. Traffic 2005; 6:942-53; PMID:16290101; http://dx.doi.org/10.1111/j.1600-0854.2005.00276.x.

22. Svitkina TM, Kovalchuk Y, Lutsko K, Lisacek F, Kolesnick R. Clathrin-mediated endocytosis: trends and perspectives. Traffic 2004; 5:939-62; PMID:15059557; http://dx.doi.org/10.1111/j.1600-0854.2004.00348.x.

23. Verstreken P, De Camilli P. The actin and endocytosis front. Trends Cell Biol 2006; 16:390-6; PMID:16865295; http://dx.doi.org/10.1016/j.tcb.2006.06.005.

24. Svitkina TM, Menger MD, Makeyev O, Rose EA, Cuppen E, et al. Clathrin interactions with the actin cytoskeleton: implications for membrane mobility. Eur J Cell Biol 2007; 86:587-600; PMID:17574948; http://dx.doi.org/10.1016/j.ejcb.2007.05.001.

25. Roninson IB, Severson EL, Kolesnick R. Mechanisms of clathrin-mediated endocytosis. Cold Spring Harb Perspect Biol 2013; 5:a012037; PMID:23303173; http://dx.doi.org/10.1101/cshperspect.a012037.